Trial Profile
A Phase Ib/II Study of Eribulin in Combination With Cyclophosphamide in Patients With Solid Tumor Malignancies.
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 02 Feb 2024
Price :
$35
*
At a glance
- Drugs Cyclophosphamide (Primary) ; Eribulin (Primary)
- Indications Advanced breast cancer; Carcinoma; Male breast cancer; Solid tumours
- Focus Adverse reactions; Therapeutic Use
- 01 Jan 2024 Results published in the Breast Cancer Research and Treatment
- 31 May 2020 Results presented at the 56th Annual Meeting of the American Society of Clinical Oncology.
- 06 Mar 2020 Status changed from active, no longer recruiting to completed.